{"id":318897,"date":"2026-03-08T08:30:23","date_gmt":"2026-03-08T08:30:23","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/318897\/"},"modified":"2026-03-08T08:30:23","modified_gmt":"2026-03-08T08:30:23","slug":"gileads-bic-len-hiv-results-highlight-valuation-gap-and-future-potential","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/318897\/","title":{"rendered":"Gilead\u2019s BIC LEN HIV Results Highlight Valuation Gap And Future Potential"},"content":{"rendered":"\n

Make better investment decisions<\/a> with Simply Wall St’s easy, visual tools that give you a competitive edge.<\/p>\n

Gilead Sciences reported positive Phase 3 results for its BIC\/LEN HIV regimen at CROI 2026.<\/p>\n

The ARTISTRY-1 and ARTISTRY-2 trials showed efficacy and safety in line with current complex and single tablet HIV therapies.<\/p>\n

BIC\/LEN is a once daily single tablet option aimed at people living with HIV, including those currently on multi pill regimens.<\/p>\n

For investors watching Gilead Sciences, NasdaqGS:GILD, the BIC\/LEN data adds a fresh clinical milestone to an already established HIV franchise. The company\u2019s shares recently traded at $143.93, with a 26.0% return over the past year and a very large 3 year gain of about 7x. Over 5 years, the stock shows a 180.1% return, which underlines how HIV research has remained central to the story.<\/p>\n

Short term returns have been softer, with a 3.4% decline over the past week and a 3.6% decline over the past month, while the stock is still up 18.4% year to date. As the BIC\/LEN program progresses, investors may focus on how these results could feed into future treatment guidelines, uptake among people on complex regimens, and the long term shape of Gilead\u2019s HIV portfolio.<\/p>\n

Stay updated on the most important news stories for Gilead Sciences<\/a> by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Gilead Sciences.<\/p>\n

\"NasdaqGS:GILD<\/a> NasdaqGS:GILD Earnings & Revenue Growth as at Mar 2026 <\/p>\n

We’ve flagged 1 risk for Gilead Sciences. See which could impact your investment.<\/a><\/p>\n

\u2696\ufe0f Price vs Analyst Target: At US$143.93, Gilead trades about 8% below the US$156.59 analyst target, which sits within the analysts’ US$118 to US$177 range.<\/p>\n

\u2705 Simply Wall St Valuation: Simply Wall St currently views the shares as trading about 50.5% below its estimated fair value.<\/p>\n

\u274c Recent Momentum: The stock has seen a 3.6% decline over the past 30 days despite the positive Phase 3 BIC\/LEN readout.<\/p>\n

There is only one way to know the right time to buy, sell or hold Gilead Sciences. Head to Simply Wall St’s company report for the latest analysis of Gilead Sciences’s fair value<\/a>.<\/p>\n

\ud83d\udcca Positive BIC\/LEN Phase 3 data supports Gilead’s established HIV franchise while the shares trade at a discount both to the analyst target and Simply Wall St’s estimated fair value.<\/p>\n

\ud83d\udcca Watch how BIC\/LEN features in future treatment guidelines, prescription trends for patients on complex regimens, and any commentary on HIV portfolio mix in upcoming earnings.<\/p>\n

\u26a0\ufe0f Simply Wall St flags one risk related to Gilead having a high level of debt, which investors may want to weigh against new product contributions over time.<\/p>\n

For the full picture including more risks and rewards, check out the complete Gilead Sciences analysis<\/a>. Alternatively, you can check out the community page for Gilead Sciences<\/a> to see how other investors believe this latest news will impact the company’s narrative.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include GILD<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Gilead…\n","protected":false},"author":2,"featured_media":318898,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[58983,134,172592,111,139,69,151977],"class_list":{"0":"post-318897","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-gilead-sciences","9":"tag-health","10":"tag-hiv-research","11":"tag-new-zealand","12":"tag-newzealand","13":"tag-nz","14":"tag-simply-wall-st"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/318897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=318897"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/318897\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/318898"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=318897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=318897"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=318897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}